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A major limitation in Tissue Engineering (TE) is the ability to control complexity within 3D engineered constructs. 
Diffusion limitations lead to the development of uncontrolled or even adverse environments leading to 
uncontrolled stem cell fate decision within the cultured tissue and cell death. Moreover the lack of control of the 
environment within these constructs makes the application of quality engineering principles such as quality by 
design (QbD) impossible. Length-scales chosen for the creation of in vitro tissues have not been chosen based 
on rational criteria and hence minimal success has been attained upon implantation. Recently bottom-up 
strategies have been introduced advocating the use of smaller tissue modules as building blocks for the formation 
of larger tissues prior to implantation.  
 
In this work we first cultured seeded human progenitor cells on non-adherent agarose surfaces containing 
microwells at their bottom, trapping the seeded cells, allowed initial condensations to take place and the formation 
of controlled-size aggregates (Figure 1A). After chondrogenic differentiation 3D cartilage intermediate µ-tissues 
where formed, positive for alcian blue and safranin-o stains indication the presence of mature cartilaginous 
extracellular matrix. These cartilaginous µ-tissues were fused via self-assembly for 24 hrs in vitro into larger 
implants with a diameter of 4 mm and implanted subcutaneously in small animal models. As control we used 
implants formed by progenitor cells cultured in pellet format in the same media formulation as the µ-tissues and 
containing the same amount of cells as the bottom-up assembled implant. Even at this scale a bone organ was 
formed in vivo containing a cortex and a bone marrow compartment while the macro-pellet demonstrated a large 
fibrotic tissue domain within the implant (Figure 1B, C).  
 
We believe that this is a first step in establishing a biomanufacruting pipe-line for the robust production of 3D 
implants/tissues for skeletal regeneration. Moreover the bone forming ability of the fused µ-tissues in their in vivo 
performance provides an unprecedented potency assay that could directly link the process environment to the 
critical quality attributes of the manufactured tissues. Although demonstrated for a skeletal application in this 
study this strategy could be applied for the manufacturing of a variety of tissues.  
  
 
Figure 1 – (A) images showing 
controlled size µ-tissues and model 
used to define their size, (B) 
Safranin-O stain of bottom-up 
assembled tissue, (C) Top down 
pellet culture explant. * denotes 
bone, & denotes bone marrow, # 
fibrotic tissue 
